ReviewJournal of molecular medicine (Berlin, Germany)2008
VMAT2 gene expression and function as it applies to imaging beta-cell mass.
Review in Journal of molecular medicine (Berlin, Germany), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 67 citations in OpenAlex.
- Roles of Pancreatic Islet Catecholamine Neurotransmitters in Glycemic Control and in Antipsychotic Drug-Induced Dysglycemia.Diabetes · 2023Review
- Delivery of therapeutic agents and cells to pancreatic islets: Towards a new era in the treatment of diabetes.Molecular aspects of medicine · 2022Review
- VMAT2 Safeguards β-Cells Against Dopamine Cytotoxicity Under High-Fat Diet-Induced Stress.Diabetes · 2020Article
- Elucidating the Relationship Between Diabetes Mellitus and Parkinson's Disease UsingFrontiers in neuroscience · 2020Review
- Molecular imaging of β-cells: diabetes and beyond.Advanced drug delivery reviews · 2019Review
- Decreased VMAT2 in the pancreas of humans with type 2 diabetes mellitus measured in vivo by PET imaging.Diabetologia · 2018Article
- Evaluation of Pancreatic VMAT2 Binding with Active and Inactive Enantiomers of [Molecular imaging and biology · 2018Article
- Evaluation of pancreatic VMAT2 binding with active and inactive enantiomers ofNuclear medicine and biology · 2016Article
- Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.Pharmacological reviews · 2016Review
- Imaging pancreatic islet cells by positron emission tomography.World journal of radiology · 2016Review
- Quantitative Impact of Plasma Clearance and Down-regulation on GLP-1 Receptor Molecular Imaging.Molecular imaging and biology · 2016Article
- A Novel Potential Positron Emission Tomography Imaging Agent for Vesicular Monoamine Transporter Type 2.PloS one · 2016Article
- A novel insulinotropic mechanism of whole grain-derived γ-oryzanol via the suppression of local dopamine DBritish journal of pharmacology · 2015Article
- Glucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications.Journal of medicinal chemistry · 2015Article
- Derivatization of (±) dihydrotetrabenazine for copper-64 labeling towards long-lived radiotracers for PET imaging of the vesicular monoamine transporter 2.Bioorganic & medicinal chemistry letters · 2014Article
- VMAT2 identified as a regulator of late-stage β-cell differentiation.Nature chemical biology · 2014Article
- Article
- Dopamine synthesis and D3 receptor activation in pancreatic β-cells regulates insulin secretion and intracellular [Ca(2+)] oscillations.Molecular endocrinology (Baltimore, Md.) · 2012Article
- Simple, rapid and reliable preparation of [¹¹C]-(+)-α-DTBZ of high quality for routine applications.Molecules (Basel, Switzerland) · 2012Article
- In vivo imaging of endogenous pancreatic β-cell mass in healthy and type 1 diabetic subjects using 18F-fluoropropyl-dihydrotetrabenazine and PET.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Diabetes mellitus is a metabolic disorder characterized by hyperglycemia. The two main forms of the disease are distinguished by different pathogenesis, natural histories, and population distributions and indicated as either type 1 (T1DM) or type 2 diabetes mellitus (T2DM). It is well established that T1DM is an autoimmune disease whereby beta-cells of pancreatic islets are destroyed leading to loss of endogenous insulin production. Albeit less dramatic, beta-cell mass (BCM) also drops in T2DM. Therefore, it is realistic to expect that noninvasive measures of BCM might provide useful information in the diabetes-care field. Preclinical studies have demonstrated that BCM measurements by positron emission tomography scanning, using the vesicular monoamine transporter type 2 (VMAT2) as a tissue-specific surrogate marker of insulin production and [11C] Dihydrotetrabenazine (DTBZ) as the radioligand specific for this molecule, is feasible in animal models. Unfortunately, the mechanisms underlying beta-cell-specific expression of VMAT2 are still largely unexplored, and a much better understanding of the regulation of VMAT2 gene expression and of its function in beta-cells will be required before the full utility of this technique in the prediction and treatment of individuals with diabetes can be understood. In this review, we summarize much of what is understood about the regulation of VMAT2 and identify questions whose answers may help in understanding what measurements of VMAT2 density mean in the context of diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.